VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Cash Flow
FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -535.60M | 3.62B | 3.32B | 2.34B | 2.71B | |||
| Depreciation Amortization | 207.20M | 181.30M | 148.30M | 125.60M | 109.50M | |||
| Income Taxes - Deferred | -348.80M | -536.50M | -275.90M | -154.60M | 277.30M | |||
| Change In Working Capital | -514.80M | -265.70M | 340.80M | -105.20M | -54.50M | |||
| Interest Paid | 30.50M | 43.10M | 52.30M | 56.30M | 54.50M | |||
| Taxes Paid | 1.08B | 1.68B | 1.06B | 476.30M | 191.80M | |||
| Other non cash items | 699.40M | 538.60M | 594.70M | 435.60M | 209.50M | |||
| OPERATING CASH FLOW | -492.60M | 3.54B | 4.13B | 2.64B | 3.25B | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -485.40M | -258.40M | -204.70M | -235.00M | -259.80M | |||
| Other Investing Activity | -3.28B | -2.88B | -116.40M | -105.90M | 359.20M | |||
| INVESTING CASH FLOW | -3.77B | -3.14B | -321.10M | -340.90M | 99.40M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -33.60M | -43.10M | -85.50M | -24.40M | -29.00M | |||
| Stock Issued/Repurchased | -1.06B | -293.00M | 186.30M | -1.32B | -274.20M | |||
| Other Financing Activity | -398.80M | -226.10M | -168.50M | -130.20M | -202.10M | |||
| FINANCING CASH FLOW | -1.49B | -562.20M | -67.70M | -1.48B | -505.30M | |||
| Exchange Rate Effect | -42.60M | 26.90M | -29.20M | -13.40M | 20.60M | |||
| CHANGE IN CASH | -5.80B | -139.70M | 3.71B | 811.20M | 2.87B | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -492.60M | 3.54B | 4.13B | 2.64B | 3.25B | |||
| Capital Expenditure | -485.40M | -258.40M | -204.70M | -235.00M | -259.80M | |||
| FREE CASH FLOW | -978.00M | 3.28B | 3.93B | 2.41B | 2.99B | |||
All data in USD